Nov. 2, 2011
On November 3, 2011, ASLAN Pharmaceuticals, a company headquartered in Singapore, and Bristol-Myers Squibb announced a strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb’s investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors. Under the terms of the agreement, ASLAN will receive exclusive rights to develop and commercialize BMS-777607 in China, Australia, Korea, Taiwan, and other selected Asian countries while Bristol-Myers Squibb retains exclusive rights in the rest of the world. ASLAN will run and fund development of BMS-777607 under a pre-agreed development program that will initially target gastric cancer and lung cancer. Financial terms were not disclosed.